Latest Insider Transactions at Exact Sciences Corp (EXAS)
This section provides a real-time view of insider transactions for Exact Sciences Corp (EXAS). The data is sourced from Form 4 filings with the SEC, which are filed by insiders of EXACT SCIENCES CORP to disclose their transactions in the company's securities. By reviewing this information, investors can gain insights into the trading activity of EXACT SCIENCES CORP's insiders and make more informed investment decisions.
Insider Transaction List
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Feb 14
2024
|
James Herriott SVP, General Counsel & Sec |
BUY
Exercise of conversion of derivative security
|
Direct |
883
+11.32%
|
-
|
|
Feb 14
2024
|
Jacob A Orville EVP, GM, Screening |
BUY
Exercise of conversion of derivative security
|
Direct |
2,031
+19.37%
|
-
|
|
Feb 14
2024
|
Sarah Condella EVP, Human Resources |
BUY
Exercise of conversion of derivative security
|
Direct |
2,031
+2.76%
|
-
|
|
Feb 14
2024
|
Kevin T Conroy President and CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
31,133
+2.45%
|
-
|
|
Feb 14
2024
|
D Scott Coward |
BUY
Exercise of conversion of derivative security
|
Direct |
3,972
+8.46%
|
-
|
|
Feb 14
2024
|
Jeffrey Thomas Elliott Chief Financial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
3,972
+50.0%
|
-
|
|
Jan 02
2024
|
Brian Baranick EVP, GM, Precision Oncology |
SELL
Open market or private sale
|
Direct |
879
-9.91%
|
$64,167
$73.5 P/Share
|
|
Jan 02
2024
|
Sarah Condella EVP, Human Resources |
SELL
Open market or private sale
|
Direct |
2,000
-2.8%
|
$146,000
$73.5 P/Share
|
|
Dec 14
2023
|
Sarah Condella EVP, Human Resources |
SELL
Open market or private sale
|
Direct |
2,000
-2.72%
|
$140,000
$70.0 P/Share
|
|
Oct 31
2023
|
James Herriott SVP, General Counsel & Sec |
BUY
Grant, award, or other acquisition
|
Direct |
68
+1.11%
|
$2,040
$30.02 P/Share
|
|
Oct 31
2023
|
Timothy J Scannell Director |
BUY
Grant, award, or other acquisition
|
Direct |
5,694
+50.0%
|
-
|
|
Oct 12
2023
|
Everett Cunningham Chief Commercial Officer |
SELL
Open market or private sale
|
Direct |
13,007
-25.55%
|
$858,462
$66.49 P/Share
|
|
Oct 11
2023
|
Everett Cunningham Chief Commercial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
27,504
+22.19%
|
-
|
|
Sep 01
2023
|
Sarah Condella EVP, Human Resources |
SELL
Bona fide gift
|
Direct |
2,391
-3.15%
|
-
|
|
Sep 01
2023
|
Sarah Condella EVP, Human Resources |
SELL
Open market or private sale
|
Direct |
4,500
-5.6%
|
$378,000
$84.36 P/Share
|
|
Aug 21
2023
|
Jeffrey Thomas Elliott Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
30,210
-100.0%
|
$2,477,220
$82.92 P/Share
|
|
Aug 07
2023
|
Brian Baranick EVP, GM, Precision Oncology |
SELL
Open market or private sale
|
Direct |
1,350
-13.21%
|
$114,750
$85.04 P/Share
|
|
Aug 04
2023
|
Brian Baranick EVP, GM, Precision Oncology |
BUY
Exercise of conversion of derivative security
|
Direct |
2,712
+20.97%
|
-
|
|
Jul 27
2023
|
James Edward Doyle |
SELL
Open market or private sale
|
Direct |
2,000
-3.7%
|
$194,000
$97.42 P/Share
|
|
Jul 19
2023
|
James Herriott SVP, General Counsel & Sec |
SELL
Open market or private sale
|
Direct |
1,300
-17.9%
|
$130,000
$100.0 P/Share
|
|
Jun 09
2023
|
James Edward Doyle |
SELL
Open market or private sale
|
Direct |
1,402
-2.53%
|
$126,180
$90.51 P/Share
|
|
Jun 09
2023
|
Katherine S Zanotti |
SELL
Open market or private sale
|
Direct |
3,027
-4.47%
|
$272,430
$90.51 P/Share
|
|
Jun 08
2023
|
Paul J Clancy |
BUY
Grant, award, or other acquisition
|
Direct |
3,599
+19.67%
|
-
|
|
Jun 08
2023
|
Pierre Jacquet Director |
BUY
Grant, award, or other acquisition
|
Direct |
4,580
+16.27%
|
-
|
|
Jun 08
2023
|
Daniel J Levangie |
BUY
Grant, award, or other acquisition
|
Direct |
4,678
+14.33%
|
-
|
|
Jun 08
2023
|
James Edward Doyle |
BUY
Grant, award, or other acquisition
|
Direct |
3,599
+6.09%
|
-
|
|
Jun 08
2023
|
Kathleen Sebelius |
BUY
Grant, award, or other acquisition
|
Direct |
3,599
+12.58%
|
-
|
|
Jun 08
2023
|
Shacey Petrovic |
BUY
Grant, award, or other acquisition
|
Direct |
3,599
+17.01%
|
-
|
|
Jun 08
2023
|
Freda C Lewis Hall Director |
BUY
Grant, award, or other acquisition
|
Direct |
3,599
+15.46%
|
-
|
|
Jun 08
2023
|
James Herriott SVP, General Counsel & Sec |
SELL
Open market or private sale
|
Direct |
1,300
-15.18%
|
$117,000
$90.0 P/Share
|
|
Jun 08
2023
|
D Scott Coward |
BUY
Grant, award, or other acquisition
|
Direct |
6,209
+13.74%
|
-
|
|
Jun 08
2023
|
Katherine S Zanotti |
BUY
Grant, award, or other acquisition
|
Direct |
3,599
+5.05%
|
-
|
|
May 26
2023
|
James Edward Doyle |
SELL
Open market or private sale
|
Direct |
2,000
-3.71%
|
$160,000
$80.62 P/Share
|
|
May 10
2023
|
Sarah Condella EVP, Human Resources |
SELL
Open market or private sale
|
Direct |
6,087
-7.05%
|
$486,960
$80.0 P/Share
|
|
May 10
2023
|
James Herriott SVP, General Counsel & Sec |
SELL
Open market or private sale
|
Direct |
1,300
-13.18%
|
$102,700
$79.85 P/Share
|
|
May 10
2023
|
Jacob A Orville EVP, GM, Screening |
SELL
Open market or private sale
|
Direct |
5,000
-43.77%
|
$400,000
$80.0 P/Share
|
|
May 01
2023
|
Kevin T Conroy President and CEO |
BUY
Grant, award, or other acquisition
|
Direct |
709
+0.06%
|
$21,270
$30.02 P/Share
|
|
May 01
2023
|
Everett Cunningham Chief Commercial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
709
+2.94%
|
$21,270
$30.02 P/Share
|
|
May 01
2023
|
Jeffrey Thomas Elliott Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
709
+2.29%
|
$21,270
$30.02 P/Share
|
|
May 01
2023
|
James Herriott SVP, General Counsel & Sec |
BUY
Grant, award, or other acquisition
|
Direct |
640
+6.09%
|
$19,200
$30.02 P/Share
|
|
May 01
2023
|
Sarah Condella EVP, Human Resources |
SELL
Open market or private sale
|
Direct |
1,000
-1.14%
|
$63,000
$63.78 P/Share
|
|
Apr 30
2023
|
Sarah Condella EVP, Human Resources |
BUY
Grant, award, or other acquisition
|
Direct |
709
+0.8%
|
$21,270
$30.02 P/Share
|
|
Apr 03
2023
|
Sarah Condella EVP, Human Resources |
SELL
Open market or private sale
|
Direct |
1,000
-1.14%
|
$67,000
$67.19 P/Share
|
|
Mar 03
2023
|
Jacob A Orville EVP, GM, Screening |
SELL
Open market or private sale
|
Direct |
5,000
-30.45%
|
$325,000
$65.0 P/Share
|
|
Mar 01
2023
|
Sarah Condella EVP, Human Resources |
SELL
Open market or private sale
|
Direct |
1,000
-1.13%
|
$62,000
$62.0 P/Share
|
|
Mar 01
2023
|
Everett Cunningham Chief Commercial Officer |
SELL
Open market or private sale
|
Direct |
3,628
-13.78%
|
$224,936
$62.01 P/Share
|
|
Feb 28
2023
|
Jeffrey Thomas Elliott Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
4,233
-12.65%
|
$258,213
$61.12 P/Share
|
|
Feb 28
2023
|
James Herriott SVP, General Counsel & Sec |
SELL
Open market or private sale
|
Direct |
2,225
-10.23%
|
$133,500
$60.55 P/Share
|
|
Feb 28
2023
|
D Scott Coward |
SELL
Open market or private sale
|
Direct |
4,153
-11.25%
|
$253,333
$61.12 P/Share
|
|
Feb 28
2023
|
Jacob A Orville EVP, GM, Screening |
SELL
Open market or private sale
|
Direct |
6,832
-15.77%
|
$409,920
$60.55 P/Share
|